<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="bvd" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">bvd</book-part-id>
      <title-group>
        <title>Best Vitelliform Macular Dystrophy</title>
        <alt-title alt-title-type="alt-title">Synonyms: Best Macular Dystrophy, Vitelliform Macular Dystrophy Type 2</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>MacDonald</surname>
            <given-names>Ian M</given-names>
          </name>
          <degrees>MDCM</degrees>
          <email>macdonal@ualberta.ca</email>
          <aff>Department of Ophthalmology<break/>University of Alberta<break/>Edmonton, Alberta, Canada</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lee</surname>
            <given-names>Thomas</given-names>
          </name>
          <degrees>MD, MSc</degrees>
          <email>thomaslee@toh.on.ca</email>
          <aff>Department of Ophthalmology<break/>University of Ottawa<break/>Ottawa, Ontario, Canada</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2003-09-30" date-type="created">
          <day>30</day>
          <month>9</month>
          <year>2003</year>
        </date>
        <date iso-8601-date="2013-12-12" date-type="updated">
          <day>12</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="bscl" document-type="chapter">Berardinelli-Seip Congenital Lipodystrophy</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="bpan" document-type="chapter">Beta-Propeller Protein-Associated Neurodegeneration</related-object>
      <abstract id="bvd.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Best vitelliform macular dystrophy is a slowly progressive macular dystrophy with onset generally in childhood and sometimes in later teenage years. Affected individuals initially have normal vision followed by decreased central visual acuity and metamorphopsia. Individuals retain normal peripheral vision and dark adaptation. Age of onset and severity of vision loss show inter- and intrafamilial variability.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of Best vitelliform macular dystrophy is based on fundus appearance, electrooculogram (EOG), and family history. Affected individuals have a typical yellow yolk-like macular lesion on fundus examination. Lesions are usually bilateral, but can be unilateral. The EOG indirectly measures the standing potential of the eye. A normal light peak/dark trough ratio (Arden ratio) is greater than 1.8. In Best vitelliform macular dystrophy, the EOG is abnormal with a reduced light peak/dark trough ratio almost always less than 1.5, typically between 1.0 and 1.3. The Arden ratio stays constant with age for these individuals. <italic toggle="yes">BEST1</italic> (<italic toggle="yes">VMD2</italic>) is the only gene in which pathogenic variants are known to cause Best vitelliform macular dystrophy.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Low vision aids as needed. Direct laser photocoagulation and anti-vascular endothelial growth factors (anti-VEGF) for choroidal neovascularization and hemorrhage.</p>
          <p><italic toggle="yes">Surveillance:</italic> Annual ophthalmologic examination for persons of all ages.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Smoking.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Best vitelliform macular dystrophy is most commonly inherited in an autosomal dominant manner; however, autosomal recessive inheritance has been reported in three families. For autosomal dominant Best vitelliform macular dystrophy:</p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with Best vitelliform macular dystrophy have an affected parent.</p>
            </list-item>
            <list-item>
              <p>The proportion of cases caused by <italic toggle="yes">de novo</italic> pathogenic variants is unknown.</p>
            </list-item>
            <list-item>
              <p>Each child of an individual with Best vitelliform macular dystrophy has a 50% chance of inheriting the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Prenatal testing is possible for families in which the pathogenic variant is known.</p>
            </list-item>
          </list>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="bvd.Diagnosis">
        <title>Diagnosis</title>
        <sec id="bvd.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The diagnosis of Best vitelliform macular dystrophy is based on fundus appearance, electrooculogram (EOG), and family history.</p>
          <p><bold>Fundus appearance.</bold> Affected individuals may have a typical yellow yolk-like macular lesion on fundus examination. Lesions are usually bilateral, but can be unilateral. Multiple lesions and lesions outside the macula occur in at least one quarter of individuals. See <xref ref-type="fig" rid="bvd.F1">Figure 1</xref>, <xref ref-type="fig" rid="bvd.F2">Figure 2</xref>, <xref ref-type="fig" rid="bvd.F3">Figure 3</xref>.</p>
          <p>The following clinical stages have been described, but it is important to note that the disease does not progress through each of these stages in every individual:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Stage 0.</bold> Normal macula. Abnormal EOG</p>
            </list-item>
            <list-item>
              <p><bold>Stage 1.</bold> Retinal pigment epithelium (RPE) disruption in the macular region. Fluorescein angiogram (FA) shows window defects.</p>
            </list-item>
            <list-item>
              <p><bold>Stage 2.</bold> Circular, well-circumscribed, yellow-opaque, homogeneous yolk-like macular lesion (vitelliform lesion) (see <xref ref-type="fig" rid="bvd.F1">Figure 1</xref>). FA reveals marked hypofluorescence in the zone covered by the lesion.</p>
            </list-item>
            <list-item>
              <p><bold>Stage 2a.</bold> Vitelliform lesion contents become less homogeneous to develop a "scrambled-egg" appearance. FA shows partial blockage of fluorescence with a non-homogeneous hyperfluorescence.</p>
            </list-item>
            <list-item>
              <p><bold>Stage 3.</bold> Pseudohypopyon phase (see <xref ref-type="fig" rid="bvd.F2">Figure 2</xref>). The lesion develops a fluid level of a yellow-colored vitelline substance. FA shows inferior hypofluorescence from the blockage by the vitelline material, along with superior hyperfluorescent defects.</p>
            </list-item>
            <list-item>
              <p><bold>Stage 4a.</bold> Orange-red lesion with atrophic RPE and visibility of the choroid. FA shows hyperfluorescence without leakage.</p>
            </list-item>
            <list-item>
              <p><bold>Stage 4b.</bold> Fibrous scarring of the macula (see <xref ref-type="fig" rid="bvd.F3">Figure 3</xref>). FA shows hyperfluorescence without leakage.</p>
            </list-item>
            <list-item>
              <p><bold>Stage 4c.</bold> Choroidal neovascularization with new vessels on the fibrous scar or appearance of subretinal hemorrhage. FA shows hyperfluorescence as a result of neovascularization and leakage.</p>
            </list-item>
          </list>
          <p>
            <bold>Electrophysiology</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The electrooculogram (EOG) measures indirectly the standing potential of the eye:</p>
              <list list-type="bullet">
                <list-item>
                  <p>A normal light peak/dark trough ratio (Arden ratio) is greater than 1.8. (Arden ratio decreases with age after the fourth decade; this value is not absolute.)</p>
                </list-item>
                <list-item>
                  <p>In individuals with Best vitelliform macular dystrophy, the EOG is usually abnormal with a reduced light peak/dark trough ratio (Arden ratio) less than 1.5, most often between 1.0 and 1.3. Note: Occasionally individuals with clinical findings of Best vitelliform macular dystrophy and a pathogenic variant in <italic toggle="yes">BEST1</italic> have a normal EOG [<xref ref-type="bibr" rid="bvd.REF.testa.2008.1467">Testa et al 2008</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>The full-field electroretinogram (ERG) is normal. Foveal ERG or multifocal ERG reveals reduced central amplitudes [<xref ref-type="bibr" rid="bvd.REF.scholl.2002.1053">Scholl et al 2002</xref>, <xref ref-type="bibr" rid="bvd.REF.palmowski.2003.145">Palmowski et al 2003</xref>]. Abnormal multifocal ERG (mfERG) recordings match areas defined as clinically abnormal by optical coherence tomography (OCT) and retinal photography [<xref ref-type="bibr" rid="bvd.REF.glybina.2006.1593">Glybina &#x00026; Frank 2006</xref>]. Scanning laser ophthalmoscope-evoked multifocal ERG (SLO-mfERG), used for topographic mapping of retinal function in individuals with Best vitelliform macular dystrophy [<xref ref-type="bibr" rid="bvd.REF.rudolph.2003.154">Rudolph &#x00026; Kalpadakis 2003</xref>], reveals significantly reduced amplitudes in the macula.</p>
            </list-item>
          </list>
          <p><bold>Color vision tests.</bold> A significant proportion of individuals have anomalous color discrimination particularly in the protan axis. Color vision changes are nonspecific and non-diagnostic.</p>
          <p><bold>Optical coherence tomography (OCT).</bold> This imaging approach can reveal the cross-sectional anatomy of the retina in individuals with Best vitelliform macular dystrophy [<xref ref-type="bibr" rid="bvd.REF.pianta.2003.203">Pianta et al 2003</xref>, <xref ref-type="bibr" rid="bvd.REF.querques.2008.501">Querques et al 2008</xref>]. OCT has defined normal retinal architecture or subtle changes in the outer retina in previtelliform clinical stages, splitting and elevation at the outer retina-retinal pigment epithelium complex in intermediate clinical stages, and thinning of the retina and retinal pigment epithelium in the atrophic clinical stage.</p>
          <p><bold>Fundus autofluorescence (AF).</bold> This imaging modality has gained prominence over the past decade as it can detect metabolic changes in the retinal pigment epithelium (RPE) and photoreceptor layers that otherwise may not be detected in color fundus photos. Increased AF has been shown to correspond to the lesions seen in the fundus [<xref ref-type="bibr" rid="bvd.REF.boon.2008.2569">Boon et al 2008</xref>].</p>
          <p><bold>Family history.</bold> Family history is consistent with autosomal dominant or autosomal recessive inheritance.</p>
        </sec>
        <sec id="bvd.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Gene.</bold>
<italic toggle="yes">BEST1</italic> is the only gene in which pathogenic variants are known to cause Best vitelliform macular dystrophy [<xref ref-type="bibr" rid="bvd.REF.marquardt.1998.1517">Marquardt et al 1998</xref>, <xref ref-type="bibr" rid="bvd.REF.petrukhin.1998.241">Petrukhin et al 1998</xref>, <xref ref-type="bibr" rid="bvd.REF.allikmets.1999.449">Allikmets et al 1999</xref>, <xref ref-type="bibr" rid="bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</xref>, <xref ref-type="bibr" rid="bvd.REF.white.2000.301">White et al 2000</xref>, <xref ref-type="bibr" rid="bvd.REF.seddon.2001.2060">Seddon et al 2001</xref>].</p>
          <p><bold>Evidence for locus heterogeneity.</bold> Individuals with Best vitelliform macular dystrophy in whom no pathogenic variants in <italic toggle="yes">BEST1</italic> could be found have been reported.</p>
          <list list-type="bullet">
            <list-item>
              <p>This may result from the failure of sequence analysis to detect exon deletions and pathogenic variants in introns or untranslated 5' and 3' regions of the gene [<xref ref-type="bibr" rid="bvd.REF.petrukhin.1998.241">Petrukhin et al 1998</xref>, <xref ref-type="bibr" rid="bvd.REF.bakall.1999.383">Bakall et al 1999</xref>, <xref ref-type="bibr" rid="bvd.REF.caldwell.1999.98">Caldwell et al 1999</xref>, <xref ref-type="bibr" rid="bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</xref>, <xref ref-type="bibr" rid="bvd.REF.white.2000.301">White et al 2000</xref>].</p>
            </list-item>
            <list-item>
              <p>It is possible that pathogenic variants in other genes can result in a similar phenotype. For example, <xref ref-type="bibr" rid="bvd.REF.boon.2007.1100">Boon et al [2007]</xref> reported a patient in whom no pathogenic variant was found in <italic toggle="yes">BEST1</italic> who had a sequence variant in the 5&#x02019; untranslated region of <italic toggle="yes">PRPH2</italic> (<italic toggle="yes">RDS</italic>). A p.Pro210Arg pathogenic variant in <italic toggle="yes">PRPH2</italic> has been found in adult-onset vitelliform macular dystrophy [<xref ref-type="bibr" rid="bvd.REF.zhuk.2006.811">Zhuk &#x00026; Edwards 2006</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Clinical testing</bold>
          </p>
          <table-wrap id="bvd.T.summary_of_molecular_genetic_testi" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Best Vitelliform Macular Dystrophy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="3" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="3" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_2">Test Method</th>
                  <th id="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_3" rowspan="3" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_3">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                </tr>
                <tr>
                  <th headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_4" id="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Family History</th>
                </tr>
                <tr>
                  <th headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_4 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_2_1" id="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_3_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Positive</th>
                  <th headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_4 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_2_1" id="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_3_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Negative</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">BEST1</italic>
                  </td>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_4 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_2_1 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_3_1" valign="middle" align="left" rowspan="1" colspan="1">96%&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_4 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_2_1 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_3_2" valign="middle" align="left" rowspan="1" colspan="1">50%-70%&#x000a0;<sup>6</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Partial or whole-gene deletions/duplications</td>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_4 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_2_1 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_3_1 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_3_2" valign="middle" colspan="2" align="left" rowspan="1">Unknown; none reported&#x000a0;<sup>8</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Targeted analysis for pathogenic variants</td>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">c.383G&#x0003e;C</td>
                  <td headers="hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_1_4 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_2_1 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_3_1 hd_h_bvd.T.summary_of_molecular_genetic_testi_1_1_3_2" valign="middle" colspan="2" align="left" rowspan="1">Majority of affected individuals in an extended Swedish kindred&#x000a0;<sup>9</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="bvd.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="bvd" object-id="bvd.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="bvd.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="bvd.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="bvd.TF.1.3">
                <label>3. </label>
                <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
              </fn>
              <fn id="bvd.TF.1.4">
                <label>4. </label>
                <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="bvd.TF.1.5">
                <label>5. </label>
                <p>Detects pathogenic variants in up to 96% of affected individuals with a positive family history [<xref ref-type="bibr" rid="bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al [2000]</xref></p>
              </fn>
              <fn id="bvd.TF.1.6">
                <label>6. </label>
                <p>In individuals with no family history of Best vitelliform macular dystrophy the variant detection rate ranges between 50% and 70% [<xref ref-type="bibr" rid="bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</xref>, <xref ref-type="bibr" rid="bvd.REF.white.2000.301">White et al 2000</xref>].</p>
              </fn>
              <fn id="bvd.TF.1.7">
                <label>7. </label>
                <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="bvd.TF.1.8">
                <label>8. </label>
                <p>No deletions or duplications in this gene have been reported to cause Best vitelliform macular dystrophy.</p>
              </fn>
              <fn id="bvd.TF.1.9">
                <label>9. </label>
                <p><italic toggle="yes">BEST1</italic> c.383G&#x0003e;C (p.Trp93Cys) variant for individuals who can trace their ancestry to a large Swedish kindred ("pedigree S1") [<xref ref-type="bibr" rid="bvd.REF.petrukhin.1998.241">Petrukhin et al 1998</xref>]</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/vaop/ncurrent/full/ejhg2011251a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="bvd.REF.ramsden.2012">Ramsden et al 2012</xref>] for information on test characteristics including sensitivity and specificity.</p>
        </sec>
        <sec id="bvd.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Targeted analysis</bold> for the c.383G&#x0003e;C pathogenic variant is recommended for individuals of Swedish ancestry who are suspected of having Best vitelliform macular dystrophy. If this variant is not found, sequence analysis of the entire gene may detect a pathogenic variant.</p>
            </list-item>
            <list-item>
              <p><bold>Single-gene testing.</bold> One strategy for molecular diagnosis of a proband suspected of having Best vitelliform macular dystrophy is sequence analysis of <italic toggle="yes">BEST1</italic>.</p>
            </list-item>
            <list-item>
              <p><bold>Multi-gene panel.</bold> For some probands, it may be appropriate to consider using an eye disorders multi-gene panel that includes <italic toggle="yes">BEST1</italic>. These panels vary by methods used and genes included; thus, the ability of a panel to detect a causative variant or variants in any given individual also varies.</p>
            </list-item>
          </list>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic adult family members (for clarification of genetic status) requires prior identification of the pathogenic variant(s) in the family.</p>
          <p><bold>Carrier testing for at-risk relatives</bold> (in those rare cases where inheritance is autosomal recessive) requires prior identification of the pathogenic variants in the family.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant(s) in the family.</p>
        </sec>
      </sec>
      <sec id="bvd.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="bvd.Clinical_Description">
          <title>Clinical Description</title>
          <p>Best vitelliform macular dystrophy is a slowly progressive macular dystrophy with onset in childhood and sometimes in later teenage years. Retinal findings are not generally present at birth and typically do not manifest until ages five to ten years. Best vitelliform macular dystrophy is characterized by normal vision followed by decreased central visual acuity and metamorphopsia (<xref ref-type="table" rid="bvd.T.stages_of_disease_progression_in_b">Table 2</xref>). Expression and age of onset are variable (<xref ref-type="table" rid="bvd.T.age_and_disease_progression_in_bes">Table 3</xref>). Some affected individuals remain asymptomatic, while others have significant visual impairment. Peripheral vision and dark adaptation remain normal.</p>
          <p>Atypical phenotypic presentations in individuals with biallelic pathogenic variants in <italic toggle="yes">BEST1</italic> have been described. Affected individuals may show multiple vitelliform lesions, lesions with fibrosis, or variable presentations within families. All affected individuals have had an abnormal EOG; some have had an abnormal ERG [<xref ref-type="bibr" rid="bvd.REF.macdonald.2012.123">MacDonald et al 2012</xref>, <xref ref-type="bibr" rid="bvd.REF.boon.2013.809">Boon et al 2013</xref>].</p>
          <p>The genetic or environmental factors that influence severity of disease are unknown.</p>
          <table-wrap id="bvd.T.stages_of_disease_progression_in_b" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Stages of Disease Progression in Best Vitelliform Macular Dystrophy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Stage</th>
                  <th id="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Signs</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">0 &#x00026; 1</td>
                  <td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>No change in stage in 10 yrs</p>
                      </list-item>
                      <list-item>
                        <p>Visual acuity of 20/20 in 75%</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2 &#x00026; 3</td>
                  <td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>For a large portion, advance in stage within 5-10 yrs</p>
                      </list-item>
                      <list-item>
                        <p>Visual acuity of 20/40 or better in majority</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">4</td>
                  <td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>No change in stage over 5 yrs for majority</p>
                      </list-item>
                      <list-item>
                        <p>10% of 4a and 16% of 4b progress to stage 4c</p>
                      </list-item>
                      <list-item>
                        <p>Visual acuity of 20/20 in 10%; 19% lose 2 lines or more in visual acuity over 8-10 yrs</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <table-wrap id="bvd.T.age_and_disease_progression_in_bes" position="anchor" orientation="portrait">
            <label>Table 3. </label>
            <caption>
              <p>Age and Disease Progression in Best Vitelliform Macular Dystrophy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Age</th>
                  <th id="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Visual Acuity</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x02264;40 yrs</td>
                  <td headers="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>In ~75%, &#x02265;20/40 in better eye</p>
                      </list-item>
                      <list-item>
                        <p>In ~66%, &#x0003c;20/40 in worse eye</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x02265;50 yrs</td>
                  <td headers="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>In ~50%, 20/70 in better eye</p>
                      </list-item>
                      <list-item>
                        <p>In 100%, &#x02264;20/100 in worse eye</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>From <xref ref-type="bibr" rid="bvd.REF.miller.1976.252">Miller et al [1976]</xref>, <xref ref-type="bibr" rid="bvd.REF.mohler.1981.688">Mohler &#x00026; Fine [1981]</xref>, <xref ref-type="bibr" rid="bvd.REF.fishman.1993.1665">Fishman et al [1993]</xref>, <xref ref-type="bibr" rid="bvd.REF.marano.2000.760">Marano et al [2000]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Histopathology.</bold> Light and electron microscopy show abnormal accumulation of lipofuscin granules within the RPE throughout the macula and also in the remainder of the retina.</p>
        </sec>
        <sec id="bvd.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Genotype-phenotype correlations have not been demonstrated.</p>
          <p>Minimal information correlates individual pathogenic variants to a specific stage of disease or degree of visual impairment. However, <xref ref-type="bibr" rid="bvd.REF.eksandh.2001.107">Eksandh et al [2001]</xref> describe a family with a p.Val89Ala substitution and a phenotype of late-onset visual failure (age 40-50 years).</p>
          <p><xref ref-type="bibr" rid="bvd.REF.mullins.2005.1588">Mullins et al [2005]</xref> describe a family with a p.Tyr227Asn substitution and a phenotype of late-onset small vitelliform lesions.</p>
          <p>Three families with compound heterozygous pathogenic variants and autosomal recessive inheritance of Best vitelliform macular dystrophy were reported [<xref ref-type="bibr" rid="bvd.REF.bitner.2011.5332">Bitner et al 2011</xref>, <xref ref-type="bibr" rid="bvd.REF.iannaccone.2011.211">Iannaccone et al 2011</xref>, <xref ref-type="bibr" rid="bvd.REF.zhao.2012.866">Zhao et al 2012</xref>]. Six children from three different families have been found to have biallelic pathogenic variants in <italic toggle="yes">BEST1</italic>. Four of the affected individuals had multiple vitelliform lesions. Two individuals were homozygous for the c.1415delT variant, one individual was a compound heterozygote for p.Arg141Ser and p.Arg141His, and three individuals were compound heterozygotes for p.Leu41Pro and p.Ile201Thr variants. Heterozygous carriers did not develop disease.</p>
        </sec>
        <sec id="bvd.Penetrance">
          <title>Penetrance</title>
          <p>Best vitelliform macular dystrophy shows generally complete penetrance, especially when the EOG is used as evidence of clinical expression. Evidence for non-penetrance has been reported.</p>
        </sec>
        <sec id="bvd.Anticipation">
          <title>Anticipation</title>
          <p>Genetic anticipation has not been reported in Best vitelliform macular dystrophy.</p>
        </sec>
        <sec id="bvd.Nomenclature">
          <title>Nomenclature</title>
          <p>The following terms are in use:</p>
          <list list-type="bullet">
            <list-item>
              <p>Best disease</p>
            </list-item>
            <list-item>
              <p>Vitelliform macular dystrophy, early onset</p>
            </list-item>
            <list-item>
              <p>Vitelliform macular dystrophy, juvenile onset</p>
            </list-item>
            <list-item>
              <p>Vitelliform macular dystrophy, adult onset</p>
            </list-item>
            <list-item>
              <p>Macular degeneration, polymorphic vitelline</p>
            </list-item>
          </list>
        </sec>
        <sec id="bvd.Prevalence">
          <title>Prevalence</title>
          <p>Best vitelliform macular dystrophy is a rare disorder. The prevalence is unknown.</p>
        </sec>
      </sec>
      <sec id="bvd.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Pathogenic variants in <italic toggle="yes">BEST1</italic> have been found in:</p>
        <list list-type="bullet">
          <list-item>
            <p>Eight individuals with bull's-eye maculopathy [<xref ref-type="bibr" rid="bvd.REF.seddon.2001.2060">Seddon et al 2001</xref>];</p>
          </list-item>
          <list-item>
            <p>Two individuals with adult vitelliform macular dystrophy (AVMD) [<xref ref-type="bibr" rid="bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</xref>] (see also <xref ref-type="sec" rid="bvd.Differential_Diagnosis">Differential Diagnosis</xref>);</p>
          </list-item>
          <list-item>
            <p>Families with autosomal dominant vitreoretinochoroidopathy (ADVIRC) associated with nanophthalmos [<xref ref-type="bibr" rid="bvd.REF.yardley.2004.3683">Yardley et al 2004</xref>]. Patients with ADVIRC have nanophthalmos, microcornea, angle closure glaucoma, congenital cataract (posterior subcapsular), and a retinal dystrophy. The retinal dystrophy is characterized by peripheral retina pigment, white preretinal opacities, apparent cystoid macular edema, retinal neovascularization, choroid atrophy, and a fibrillar condensation of the vitreous. The ERG and EOG are abnormal. ADVIRC is caused by distinct pathogenic variants in <italic toggle="yes">BEST1</italic> that alter pre-mRNA splicing [<xref ref-type="bibr" rid="bvd.REF.burgess.2009.620">Burgess et al 2009</xref>].</p>
          </list-item>
          <list-item>
            <p>Individuals with autosomal recessive bestrophinopathy (ARB):</p>
            <list list-type="bullet">
              <list-item>
                <p>Pathogenic variants in both alleles of <italic toggle="yes">BEST1</italic> (biallelic mutation) that result in a more severe retinopathy than Best vitelliform macular dystrophy have been seen in individuals of Swedish ancestry who have two missense variants [<xref ref-type="bibr" rid="bvd.REF.schatz.2006.51">Schatz et al 2006</xref>].</p>
              </list-item>
              <list-item>
                <p>Similarly, an autosomal recessive bestrophinopathy [<xref ref-type="bibr" rid="bvd.REF.burgess.2008.19">Burgess et al 2008</xref>] has been identified in individuals with a cone-rod dystrophy, an abnormal ERG, and a markedly reduced Arden ratio of the EOG. Affected individuals have white subretinal deposits and macular subretinal fluid which may suggest the diagnosis. Heterozygotes, who have either a deletion in one allele or a nonsense variant, do not have clinical signs or electrophysiologic abnormalities.</p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="bvd.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Best vitelliform macular dystrophy is readily recognized by its distinct macular lesion. The following retinopathies may be confused with Best vitelliform macular dystrophy [<xref ref-type="bibr" rid="bvd.REF.allikmets.1999.449">Allikmets et al 1999</xref>, <xref ref-type="bibr" rid="bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</xref>, <xref ref-type="bibr" rid="bvd.REF.white.2000.301">White et al 2000</xref>, <xref ref-type="bibr" rid="bvd.REF.seddon.2001.2060">Seddon et al 2001</xref>]:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Adult vitelliform macular dystrophy (AVMD).</bold> This autosomal dominant disorder, characterized by the presence of bilateral, small, circular, yellow, symmetrical, subretinal lesions with drusen-like deposits, affects mainly middle-aged individuals. The funduscopic findings can easily be mistaken for Best vitelliform macular dystrophy, but the EOG is normal or only slightly reduced in these individuals. Pathogenic variants in <italic toggle="yes">PRPH2</italic> (<italic toggle="yes">RDS</italic>) (which encodes the protein peripherin) and <italic toggle="yes">BEST1</italic> have been found in a small number of individuals with AVMD, demonstrating the genetic heterogeneity of the disorder [<xref ref-type="bibr" rid="bvd.REF.renner.2004.929">Renner et al 2004</xref>, <xref ref-type="bibr" rid="bvd.REF.yu.2006.4956">Yu et al 2006</xref>, <xref ref-type="bibr" rid="bvd.REF.zhuk.2006.811">Zhuk &#x00026; Edwards 2006</xref>]. AVMD shows significant phenotypic overlap with Best vitelliform macular dystrophy. Using OCT, <xref ref-type="bibr" rid="bvd.REF.hayami.2003.53">Hayami et al [2003]</xref> found that the structure of the vitelliform lesions in the two disorders were similar.</p>
          </list-item>
          <list-item>
            <p><bold>Age-related macular degeneration (AMD).</bold> This common disorder is characterized by drusen, RPE disruption, and choroidal neovascularization. Multiple lines of evidence indicate that AMD has a familial component. Pathogenic variants in a number of genes (including <italic toggle="yes">CFH</italic>, <italic toggle="yes">CFB</italic>, <italic toggle="yes">ABCA4</italic>, <italic toggle="yes">TIMP3</italic>, and <italic toggle="yes">EFEMP1</italic>) have been associated with AMD [<xref ref-type="bibr" rid="bvd.REF.patel.2008.768">Patel et al 2008</xref>]. Pathogenic variants in <italic toggle="yes">BEST1</italic> are rare in cases of AMD [<xref ref-type="bibr" rid="bvd.REF.allikmets.1999.449">Allikmets et al 1999</xref>, <xref ref-type="bibr" rid="bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</xref>, <xref ref-type="bibr" rid="bvd.REF.lotery.2000.1291">Lotery et al 2000</xref>, <xref ref-type="bibr" rid="bvd.REF.seddon.2001.2060">Seddon et al 2001</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Bull's-eye maculopathy.</bold> This descriptive clinical diagnosis is typified by an annular region with depigmentation of central RPE in the macula [<xref ref-type="bibr" rid="bvd.REF.seddon.2001.2060">Seddon et al 2001</xref>]. The phenotype can be seen in individuals with cone dystrophy, cone-rod dystrophy, Stargardt disease, chloroquine maculopathy, and other maculopathies. <xref ref-type="bibr" rid="bvd.REF.seddon.2001.2060">Seddon et al [2001]</xref> found one individual with a bull's-eye maculopathy who had a pathogenic variant in <italic toggle="yes">BEST1</italic>.</p>
          </list-item>
        </list>
      </sec>
      <sec id="bvd.Management">
        <title>Management</title>
        <sec id="bvd.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To determine the stage of disease and needs in an individual diagnosed with Best vitelliform macular dystrophy, ophthalmologic examination should be performed. Medical genetics consultation may also be considered.</p>
        </sec>
        <sec id="bvd.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Low vision aids provide benefit for those individuals with significant deterioration in visual acuity.</p>
          <p>Stage 4c fundus lesions or choroidal neovascularization and hemorrhage can be managed by direct laser photocoagulation. <xref ref-type="bibr" rid="bvd.REF.marano.2000.760">Marano et al [2000]</xref> suggested a conservative approach in the treatment of choroidal neovascularization based on two individuals with Best vitelliform macular dystrophy whose visual acuity improved. No clinical trials comparing the efficacy of laser photocoagulation to conservative treatment have been conducted.</p>
          <p>Anti-VEGF (vascular endothelial growth factor) agents are the standard treatment for individuals with subfoveal choroidal neovascularization (CNV). <xref ref-type="bibr" rid="bvd.REF.leu.2007.1723">Leu et al [2007]</xref> injected intravitreal bevacizumab in a 13 year-old with Best vitelliform macular dystrophy and CNV, hastening visual recovery and regression of the CNV. Intravitreal ranibizumab has also been used with success [<xref ref-type="bibr" rid="bvd.REF.querques.2009.2960">Querques et al 2009</xref>]. There are no reports on the use of aflibercept. Long-term follow up of these affected individuals is unknown. There are currently no clinical trials to demonstrate the effectiveness of anti-VEGF agents on CNV in Best vitelliform macular dystrophy.</p>
          <p><xref ref-type="bibr" rid="bvd.REF.andrade.2003.1179">Andrade et al [2003]</xref> performed photodynamic therapy (PDT) using verteporfin for CNV on one person with Best vitelliform macular dystrophy. The CNV regressed and the subretinal hemorrhage resolved. The authors suggested that PDT may be an option for treatment of CNV in Best vitelliform macular dystrophy.</p>
          <p>Genetic counseling and occupational counseling should be offered.</p>
        </sec>
        <sec id="bvd.Surveillance">
          <title>Surveillance</title>
          <p>Ophthalmologic examination should be performed annually to monitor the progression of the fundus lesions; in childhood, annual examinations are important in preventing the development of amblyopia. Affected individuals should be advised to see their ophthalmologist in the event of decreased vision or metamorphopsia, which could be signs of CNV.</p>
        </sec>
        <sec id="bvd.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Cessation of smoking helps prevent neovascularization of the retina [<xref ref-type="bibr" rid="bvd.REF.clemons.2005.533">Clemons et al 2005</xref>].</p>
        </sec>
        <sec id="bvd.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="bvd.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="bvd.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="bvd.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="bvd.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Best vitelliform macular dystrophy is most commonly inherited in an autosomal dominant manner. However, three families with compound heterozygous pathogenic variants and autosomal recessive inheritance have been described [<xref ref-type="bibr" rid="bvd.REF.bitner.2011.5332">Bitner et al 2011</xref>, <xref ref-type="bibr" rid="bvd.REF.iannaccone.2011.211">Iannaccone et al 2011</xref>, <xref ref-type="bibr" rid="bvd.REF.zhao.2012.866">Zhao et al 2012</xref>].</p>
        </sec>
        <sec id="bvd.Risk_to_Family_Members__Autosomal_Do">
          <title>Risk to Family Members &#x02014; Autosomal Dominant Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with Best vitelliform macular dystrophy have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with Best vitelliform macular dystrophy may have the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant [<xref ref-type="bibr" rid="bvd.REF.apushkin.2006.887">Apushkin et al 2006</xref>, <xref ref-type="bibr" rid="bvd.REF.li.2006.408">Li et al 2006</xref>, <xref ref-type="bibr" rid="bvd.REF.marchant.2007.e70">Marchant et al 2007</xref>, <xref ref-type="bibr" rid="bvd.REF.atchaneeyasakul.2008.139">Atchaneeyasakul et al 2008</xref>, <xref ref-type="bibr" rid="bvd.REF.testa.2008.1467">Testa et al 2008</xref>]. The proportion of cases caused by a <italic toggle="yes">de novo</italic> pathogenic variant is unknown.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include funduscopic examination. Given that the fundus may appear normal in affected individuals, an EOG or molecular genetic testing (if the pathogenic variant in the family has been identified) can be definitive in the diagnosis of the disease [<xref ref-type="bibr" rid="bvd.REF.white.2000.301">White et al 2000</xref>]. The disease may occur in simplex cases (i.e., a single occurrence in a family) [<xref ref-type="bibr" rid="bvd.REF.palomba.2000.260">Palomba et al 2000</xref>].</p>
            </list-item>
          </list>
          <p>Note: Although most individuals diagnosed with Best vitelliform macular dystrophy have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected or has the pathogenic variant, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected and do not have the pathogenic variant, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant identified in the proband cannot be detected in DNA extracted from the leukocytes of either parent, two possible explanations are germline mosaicism in a parent or a <italic toggle="yes">de novo</italic> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with Best vitelliform macular dystrophy has a 50% chance of inheriting the pathogenic variant.</p>
          <p>
            <bold>Other family members of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is affected, his or her family members are at risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="bvd.Risk_to_Family_Members__Autosomal_Re">
          <title>Risk to Family Members &#x02014; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes and therefore carry one mutant allele.</p>
            </list-item>
            <list-item>
              <p>To date, carriers of the variants associated with autosomal recessive Best vitelliform macular dystrophy are clinically unaffected [<xref ref-type="bibr" rid="bvd.REF.zhao.2012.866">Zhao et al 2012</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) of variants known to be associated with autosomal recessive Best vitelliform macular dystrophy are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The offspring of an individual with autosomal recessive Best vitelliform macular dystrophy are obligate heterozygotes for a pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) of variants known to be associated with autosomal recessive Best vitelliform macular dystrophy are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="bvd.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family are known.</p>
        </sec>
        <sec id="bvd.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Specific risk issues.</bold> The age of onset, clinical manifestations of the disease and degree of functional impairment in an affected individual cannot be predicted.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a <italic toggle="yes">de novo</italic> pathogenic variant. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling&#x000a0;(including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="bvd.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the pathogenic variant(s) have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing for this disease/gene or custom prenatal testing.</p>
          <p>Requests for prenatal testing for conditions which (like Best vitelliform macular dystrophy) do not affect intellect or life span are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variant(s) have been identified.</p>
        </sec>
      </sec>
      <sec id="bvd.Resources">
        <title>Resources</title>
      </sec>
      <sec id="bvd.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="bvd.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p><xref ref-type="bibr" rid="bvd.REF.sun.2002.4008">Sun et al [2002]</xref> showed the existence of a new chloride channel family that includes Best vitelliform macular dystrophy. They used heterologous expression studies to demonstrate that human, <italic toggle="yes">Drosophila</italic>, and <italic toggle="yes">C. elegans</italic> bestrophin homologs form oligomeric chloride channels. Human bestrophin was sensitive to intracellular calcium. Fifteen pathogenic missense variants were associated with reduced or abolished membrane current. <xref ref-type="bibr" rid="bvd.REF.marmorstein.2002.30591">Marmorstein et al [2002]</xref> demonstrated that bestrophin undergoes dephosphorylation by a protein phosphatase. This finding suggests that bestrophin participates in a signal transduction pathway that may be related to the modulation of the light peak on the EOG. Despite the current genetic and molecular information of Best vitelliform macular dystrophy, the pathogenesis remains unexplained.</p>
          <p><bold>Normal allelic variants.</bold>
<italic toggle="yes">BEST1</italic> has 11 exons. Most of the frequent polymorphisms and rare variants occur within non-coding regions or do not result in an amino acid substitution [<xref ref-type="bibr" rid="bvd.REF.white.2000.301">White et al 2000</xref>]. <xref ref-type="bibr" rid="bvd.REF.allikmets.1999.449">Allikmets et al [1999]</xref> also described three rare amino acid substitutions of unknown significance located at the C-terminus (p.Glu525Ala, p.Glu557Lys, and p.Thr561Ala).</p>
          <p><bold>Pathogenic allelic variants.</bold> A spectrum of missense variants have been identified [<xref ref-type="bibr" rid="bvd.REF.marquardt.1998.1517">Marquardt et al 1998</xref>, <xref ref-type="bibr" rid="bvd.REF.petrukhin.1998.241">Petrukhin et al 1998</xref>, <xref ref-type="bibr" rid="bvd.REF.allikmets.1999.449">Allikmets et al 1999</xref>, <xref ref-type="bibr" rid="bvd.REF.bakall.1999.383">Bakall et al 1999</xref>, <xref ref-type="bibr" rid="bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</xref>, <xref ref-type="bibr" rid="bvd.REF.white.2000.301">White et al 2000</xref>, <xref ref-type="bibr" rid="bvd.REF.seddon.2001.2060">Seddon et al 2001</xref>, <xref ref-type="bibr" rid="bvd.REF.kr_mer.2003.418">Kr&#x000e4;mer et al 2003</xref>]. <xref ref-type="bibr" rid="bvd.REF.white.2000.301">White et al [2000]</xref> reviewed 48 reported pathogenic variants in <italic toggle="yes">BEST1</italic>: 45 missense variants, two deletions, and one splice site variant. The majority of the variants occur in the first 50% of the protein, in four unique clusters (exon 2, 4, 6, and 8), suggesting possible regions of functional importance [<xref ref-type="bibr" rid="bvd.REF.white.2000.301">White et al 2000</xref>]. (For more information, see <related-object source-id="gene" document-id="bvd" object-id="bvd.molgen.TA">Table A. Genes and Databases</related-object>.)</p>
          <p>One deletion was reported by <xref ref-type="bibr" rid="bvd.REF.caldwell.1999.98">Caldwell et al [1999]</xref> involving two base pairs that led to a shift in the reading frame and truncation of the protein at amino acid 513. A splice variant affecting the donor site of exon 5 was reported by <xref ref-type="bibr" rid="bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al [2000]</xref>.</p>
          <p><bold>Normal gene product.</bold> Bestrophin has 585 amino acids and a size of 68 kd [<xref ref-type="bibr" rid="bvd.REF.petrukhin.1998.241">Petrukhin et al 1998</xref>]. The hydropathy profile predicts at least four putative transmembrane domains. Bestrophin has been found to be highly expressed by the RPE and was localized to the basolateral plasma membrane [<xref ref-type="bibr" rid="bvd.REF.marmorstein.2000.12758">Marmorstein et al 2000</xref>]. Bestrophin functions either as a chloride channel or as a regulator of voltage-gated calcium channels in the RPE [<xref ref-type="bibr" rid="bvd.REF.hartzell.2008.639">Hartzell et al 2008</xref>, <xref ref-type="bibr" rid="bvd.REF.yu.2008.5660">Yu et al 2008</xref>].</p>
          <p><bold>Abnormal gene product.</bold> Pathogenic variants in <italic toggle="yes">BEST1</italic> alter the function of bestrophin and ion transport by the RPE, resulting in the accumulation of fluid between the RPE and the photoreceptors [<xref ref-type="bibr" rid="bvd.REF.qu.2006.5411">Qu et al 2006</xref>, <xref ref-type="bibr" rid="bvd.REF.yu.2007.4694">Yu et al 2007</xref>, <xref ref-type="bibr" rid="bvd.REF.hartzell.2008.639">Hartzell et al 2008</xref>].</p>
          <p>Note that carriers of variants found to cause AR disease are asymptomatic [<xref ref-type="bibr" rid="bvd.REF.zhao.2012.866">Zhao et al 2012</xref>]. This is postulated to be due to the fact that the causative variants, when heterozygous, allow the protein to retain a sufficient level of functioning as an ion channel or an ion channel regulator.</p>
        </sec>
      </sec>
      <sec id="bvd.References">
        <title>References</title>
        <sec id="bvd.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="bvd.Literature_Cited.reflist0">
            <ref id="bvd.REF.allikmets.1999.449">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allikmets</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seddon</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernstein</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutchinson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atkinson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerrard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metzker</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wadelius</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caskey</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dean</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrukhin</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Evaluation of the Best disease gene in patients with age-related macular degeneration and other maculopathies.</article-title>
                <source>Hum Genet</source>
                <volume>104</volume>
                <fpage>449</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">10453731</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.andrade.2003.1179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andrade</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farah</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease.</article-title>
                <source>Am J Ophthalmol</source>
                <volume>136</volume>
                <fpage>1179</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">14644242</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.apushkin.2006.887">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Apushkin</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fishman</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>EM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Novel de novo mutation in a patient with Best macular dystrophy.</article-title>
                <source>Arch Ophthalmol</source>
                <volume>124</volume>
                <fpage>887</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16769844</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.atchaneeyasakul.2008.139">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Atchaneeyasakul</surname>
                    <given-names>LO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jinda</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakolsatayadorn</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trinavarat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruangvoravate</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thanasombatskul</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thongnoppakhun</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Limwongse</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Mutation analysis of the VMD2 gene in Thai families with Best macular dystrophy.</article-title>
                <source>Ophthalmic Genet</source>
                <volume>29</volume>
                <fpage>139</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">18766995</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.bakall.1999.383">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bakall</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marknell</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingvast</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koisti</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandgren</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergen</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreasson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrukhin</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wadelius</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>The mutation spectrum of the bestrophin protein &#x02014; functional implications.</article-title>
                <source>Hum Genet</source>
                <volume>104</volume>
                <fpage>383</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10394929</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.bitner.2011.5332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bitner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizrahi-Meissonnier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griefner</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erdinest</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharon</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banin</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A homozygous frameshift mutation in BEST1 causes the classical form of Best disease in an autosomal recessive mode.</article-title>
                <source>Invest Ophthalmol Vis Sci</source>
                <volume>52</volume>
                <fpage>5332</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21467170</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.boon.2007.1100">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boon</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klevering</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>den Hollander</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zonneveld</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theelen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoyng</surname>
                    <given-names>CB</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Clinical and genetic heterogeneity in multifocal vitelliform dystrophy.</article-title>
                <source>Arch Ophthalmol</source>
                <volume>125</volume>
                <fpage>1100</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17698758</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.boon.2008.2569">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boon</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klevering</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keunen</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoyng</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theelen</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Fundus fluorescence imaging of retinal dystrophies.</article-title>
                <source>Vision Res</source>
                <volume>48</volume>
                <fpage>2569</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">18289629</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.burgess.2009.620">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burgess</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacLaren</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidson</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urquhart</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holder</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robson</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keefe</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manson</surname>
                    <given-names>FD</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>ADVIRC is caused by distinct mutations in BEST1 that alter pre-mRNA splicing.</article-title>
                <source>J Med Genet</source>
                <volume>46</volume>
                <fpage>620</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18611979</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.boon.2013.809">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boon</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Born</surname>
                    <given-names>LI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keunen</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergen</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Booij</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riemslag</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florijn</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Schooneveld</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Autosomal&#x000a0;recessive&#x000a0;bestrophinopathy: differential diagnosis and treatment options.</article-title>
                <source>Ophthalmology</source>
                <volume>120</volume>
                <fpage>809</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">23290749</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.burgess.2008.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burgess</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millar</surname>
                    <given-names>ID</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urquhart</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fearon</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Baere</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robson</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wright</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kestelyn</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holder</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webster</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manson</surname>
                    <given-names>FD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>GC</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Biallelic mutation of BEST1 causes a distinct retinopathy in humans.</article-title>
                <source>Am J Hum Genet</source>
                <volume>82</volume>
                <fpage>19</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">18179881</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.caldwell.1999.98">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Caldwell</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kakuk</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griesinger</surname>
                    <given-names>IB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simpson</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nowak</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Small</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maumenee</surname>
                    <given-names>IH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenfeld</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sieving</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shows</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayyagari</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Bestrophin gene mutations in patients with Best vitelliform macular dystrophy.</article-title>
                <source>Genomics</source>
                <volume>58</volume>
                <fpage>98</fpage>
                <lpage>101</lpage>
                <pub-id pub-id-type="pmid">10331951</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.clemons.2005.533">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clemons</surname>
                    <given-names>TE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milton</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seddon</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferris</surname>
                    <given-names>FL</given-names>
                    <suffix>3rd</suffix>
                  </name>
                  <collab>Age-Related Eye Disease Study Research Group</collab>
                </person-group>
                <year>2005</year>
                <article-title>Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19.</article-title>
                <source>Ophthalmology</source>
                <volume>112</volume>
                <fpage>533</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15808240</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.eksandh.2001.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eksandh</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakall</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wadelius</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andr&#x000e9;asson</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Best's vitelliform macular dystrophy caused by a new mutation (Val89Ala) in the VMD2 gene.</article-title>
                <source>Ophthalmic Genet</source>
                <volume>22</volume>
                <fpage>107</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">11449320</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.fishman.1993.1665">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fishman</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baca</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alexander</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Derlacki</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glenn</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viana</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Visual acuity in patients with best vitelliform macular dystrophy.</article-title>
                <source>Ophthalmology</source>
                <volume>100</volume>
                <fpage>1665</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">8233392</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.glybina.2006.1593">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Glybina</surname>
                    <given-names>IV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frank</surname>
                    <given-names>RN</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Localization of multifocal electroretinogram abnormalities to the lesion site: findings in a family with Best disease.</article-title>
                <source>Arch Ophthalmol</source>
                <volume>124</volume>
                <fpage>1593</fpage>
                <lpage>600</lpage>
                <pub-id pub-id-type="pmid">17102007</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.hartzell.2008.639">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hartzell</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qu</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiao</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chien</surname>
                    <given-names>LT</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Molecular physiology of bestrophins: multifunctional membrane proteins linked to best disease and other retinopathies.</article-title>
                <source>Physiol Rev</source>
                <volume>88</volume>
                <fpage>639</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">18391176</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.hayami.2003.53">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hayami</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decock</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brabant</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Kerckhoven</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lafaut</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Laey</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Optical coherence tomography of adult-onset vitelliform dystrophy.</article-title>
                <source>Bull Soc Belge Ophtalmol</source>
                <volume>289</volume>
                <fpage>53</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">14619630</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.iannaccone.2011.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Iannaccone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerr</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinnick</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calzada</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>EM</given-names>
                  </name>
                </person-group>
                <article-title>Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications.</article-title>
                <source>Arch Ophthalmol.</source>
                <year>2011</year>
                <volume>129</volume>
                <fpage>211</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21320969</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.kr_mer.2003.418">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kr&#x000e4;mer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohr</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kellner</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudolph</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>BH</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Ten novel mutations in VMD2 associated with Best macular dystrophy (BMD).</article-title>
                <source>Hum Mutat</source>
                <volume>22</volume>
                <fpage>418</fpage>
                <pub-id pub-id-type="pmid">14517959</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.kr_mer.2000.286">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kr&#x000e4;mer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pauleikhoff</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gehrig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passmore</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivera</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudolph</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kellner</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrassi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenz</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohrschneider</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blankenagel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jurklies</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schilling</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000fc;tt</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holz</surname>
                    <given-names>FG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>BH</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult vitelliform macular dystrophy but not age-related macular degeneration.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>8</volume>
                <fpage>286</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">10854112</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.leu.2007.1723">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schrage</surname>
                    <given-names>NF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Degenring</surname>
                    <given-names>RF</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Choroidal neovascularisation secondary to Best's disease in a 13-year-old boy treated by intravitreal bevacizumab.</article-title>
                <source>Graefes Arch Clin Exp Ophthalmol</source>
                <volume>245</volume>
                <fpage>1723</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17605026</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.lotery.2000.1291">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lotery</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munier</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fishman</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weleber</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobson</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Affatigato</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nichols</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schorderet</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sheffield</surname>
                    <given-names>VC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>EM</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Allelic variation in the VMD2 gene in best disease and age-related macular degeneration.</article-title>
                <source>Invest Ophthalmol Vis Sci</source>
                <volume>41</volume>
                <fpage>1291</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10798642</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.li.2006.408">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dong</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamaya</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>A novel mutation of the VMD2 gene in a Chinese family with best vitelliform macular dystrophy.</article-title>
                <source>Ann Acad Med Singapore</source>
                <volume>35</volume>
                <fpage>408</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">16865191</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.macdonald.2012.123">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gudiseva</surname>
                    <given-names>HV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villanueva</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greve</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caruso</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayyagari</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Phenotype and genotype of patients with autosomal recessive bestrophinopathy.</article-title>
                <source>Ophthalmic Genet</source>
                <volume>33</volume>
                <fpage>123</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21809908</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.marano.2000.760">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marano</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deutman</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leys</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aandekerk</surname>
                    <given-names>AL</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Hereditary retinal dystrophies and choroidal neovascularization.</article-title>
                <source>Graefes Arch Clin Exp Ophthalmol</source>
                <volume>238</volume>
                <fpage>760</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11045344</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.marchant.2007.e70">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marchant</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bigot</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roche</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonneau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drouin-Garraud</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schorderet</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Neindre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menasche</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dufier</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischmeister</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartzell</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abitbol</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy.</article-title>
                <source>J Med Genet</source>
                <volume>44</volume>
                <fpage>e70</fpage>
                <pub-id pub-id-type="pmid">17287362</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.marmorstein.2000.12758">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marmorstein</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marmorstein</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rayborn</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollyfield</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrukhin</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>97</volume>
                <fpage>12758</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">11050159</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.marmorstein.2002.30591">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marmorstein</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaughlin</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanton</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crabb</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marmorstein</surname>
                    <given-names>AD</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Bestrophin interacts physically and functionally with protein phosphatase 2A.</article-title>
                <source>J Biol Chem</source>
                <volume>277</volume>
                <fpage>30591</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12058047</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.marquardt.1998.1517">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marquardt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;hr</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passmore</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kr&#x000e4;mer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivera</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>BH</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease).</article-title>
                <source>Hum Mol Genet</source>
                <volume>7</volume>
                <fpage>1517</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">9700209</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.miller.1976.252">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bresnick</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chandra</surname>
                    <given-names>SR</given-names>
                  </name>
                </person-group>
                <year>1976</year>
                <article-title>Choroidal neovascular membrane in Best's vitelliform macular dystrophy.</article-title>
                <source>Am J Ophthalmol</source>
                <volume>82</volume>
                <fpage>252</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">949077</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.mohler.1981.688">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mohler</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fine</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <year>1981</year>
                <article-title>Long-term evaluation of patients with Best's vitelliform dystrophy.</article-title>
                <source>Ophthalmology</source>
                <volume>88</volume>
                <fpage>688</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">7267039</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.mullins.2005.1588">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mullins</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oh</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heffron</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hageman</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>EM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Late development of vitelliform lesions and flecks in a patient with best disease: clinicopathologic correlation.</article-title>
                <source>Arch Ophthalmol</source>
                <volume>123</volume>
                <fpage>1588</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">16286623</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.palmowski.2003.145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Palmowski</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allgayer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinemann-Vernaleken</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruprecht</surname>
                    <given-names>KW</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Detection of retinal dysfunction in vitelliform macular dystrophy using the multifocal ERG (MF-ERG).</article-title>
                <source>Doc Ophthalmol</source>
                <volume>106</volume>
                <fpage>145</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">12678279</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.palomba.2000.260">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Palomba</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rozzo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angius</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierrottet</surname>
                    <given-names>CO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orzalesi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirastu</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>A novel spontaneous missense mutation in VMD2 gene is a cause of a best macular dystrophy sporadic case.</article-title>
                <source>Am J Ophthalmol</source>
                <volume>129</volume>
                <fpage>260</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">10682987</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.patel.2008.768">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adewoyin</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chong</surname>
                    <given-names>NV</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Age-related macular degeneration: a perspective on genetic studies.</article-title>
                <source>Eye</source>
                <volume>22</volume>
                <fpage>768</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">17491602</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.petrukhin.1998.241">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Petrukhin</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koisti</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakall</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xie</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marknell</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandgren</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forsman</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmgren</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreasson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vujic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergen</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGarty-Dugan</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figueroa</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metzker</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caskey</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wadelius</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Identification of the gene responsible for Best macular dystrophy.</article-title>
                <source>Nat Genet</source>
                <volume>19</volume>
                <fpage>241</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9662395</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.pianta.2003.203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pianta</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aleman</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cideciyan</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunness</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campochiaro</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campochiaro</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zack</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobson</surname>
                    <given-names>SG</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>In vivo micropathology of Best macular dystrophy with optical coherence tomography.</article-title>
                <source>Exp Eye Res</source>
                <volume>76</volume>
                <fpage>203</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">12565808</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.qu.2006.5411">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Qu</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chien</surname>
                    <given-names>LT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cui</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartzell</surname>
                    <given-names>HC</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>The anion-selective pore of the bestrophins, a family of chloride channels associated with retinal degeneration.</article-title>
                <source>J Neurosci</source>
                <volume>26</volume>
                <fpage>5411</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16707793</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.querques.2008.501">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Querques</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Regenbogen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quijano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delphin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soubrane</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Souied</surname>
                    <given-names>EH</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>High-definition optical coherence tomography features in vitelliform macular dystrophy.</article-title>
                <source>Am J Ophthalmol</source>
                <volume>146</volume>
                <fpage>501</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18619572</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.querques.2009.2960">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Querques</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zerbib</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santacroce</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margaglione</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delphin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rozet</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delle Noci</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soubrane</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Souied</surname>
                    <given-names>EH</given-names>
                  </name>
                </person-group>
                <article-title>Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene.</article-title>
                <source>Mol Vis.</source>
                <year>2009</year>
                <volume>15</volume>
                <fpage>2960</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">20057903</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.ramsden.2012">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidson</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webster</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>GTCM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manson</surname>
                    <given-names>FDC</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: BEST1-related dystrophies (Bestrophinopathies)</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2012</year>
                <volume>20</volume>
                <issue>5</issue>
                <pub-id pub-id-type="pmid">22234150</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.renner.2004.929">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Renner</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tillack</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraus</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wissinger</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohr</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kellner</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foerster</surname>
                    <given-names>MH</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Morphology and functional characteristics in adult vitelliform macular dystrophy.</article-title>
                <source>Retina</source>
                <volume>24</volume>
                <fpage>929</fpage>
                <lpage>39</lpage>
                <pub-id pub-id-type="pmid">15579992</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.rudolph.2003.154">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rudolph</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalpadakis</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Topographic mapping of retinal function with the SLO-mfERG under simultaneous control of fixation in Best's disease.</article-title>
                <source>Ophthalmologica</source>
                <volume>217</volume>
                <fpage>154</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12592056</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.schatz.2006.51">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schatz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klar</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andr&#x000e9;asson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponjavic</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahl</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2.</article-title>
                <source>Ophthalmic Genet</source>
                <volume>27</volume>
                <fpage>51</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16754206</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.scholl.2002.1053">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scholl</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuster</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vonthein</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zrenner</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Mapping of retinal function in Best macular dystrophy using multifocal electroretinography.</article-title>
                <source>Vision Res</source>
                <volume>42</volume>
                <fpage>1053</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">11934455</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.seddon.2001.2060">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seddon</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Afshari</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernstein</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chong</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutchinson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrukhin</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allikmets</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Assessment of mutations in the Best macular dystrophy (VMD2) gene in patients with adult-onset foveomacular vitelliform dystrophy, age-related maculopathy, and bull's-eye maculopathy.</article-title>
                <source>Ophthalmology</source>
                <volume>108</volume>
                <fpage>2060</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11713080</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.sun.2002.4008">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsunenari</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yau</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nathans</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>The vitelliform macular dystrophy protein defines a new family of chloride channels.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>99</volume>
                <fpage>4008</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">11904445</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.testa.2008.1467">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passerini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sodi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Iorio</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Interlandi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Della Corte</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menchini</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torricelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonelli</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A normal electro-oculography in a family affected by best disease with a novel spontaneous mutation of the BEST1 gene.</article-title>
                <source>Br J Ophthalmol</source>
                <volume>92</volume>
                <fpage>1467</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">18703557</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.white.2000.301">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquardt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>BH</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>VMD2 mutations in vitelliform macular dystrophy (Best disease) and other maculopathies.</article-title>
                <source>Hum Mutat</source>
                <volume>15</volume>
                <fpage>301</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10737974</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.yardley.2004.3683">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yardley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hart-Holden</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lafaut</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loeys</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messiaen</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perveen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reddy</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhattacharya</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Traboulsi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baralle</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Laey</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puech</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kestelyn</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manson</surname>
                    <given-names>FD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>GC</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC).</article-title>
                <source>Invest Ophthalmol Vis Sci</source>
                <volume>45</volume>
                <fpage>3683</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15452077</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.yu.2006.4956">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cui</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartzell</surname>
                    <given-names>HC</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>The bestrophin mutation A243V, linked to adult-onset vitelliform macular dystrophy, impairs its chloride channel function.</article-title>
                <source>Invest Ophthalmol Vis Sci</source>
                <volume>47</volume>
                <fpage>4956</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">17065513</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.yu.2007.4694">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qu</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cui</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartzell</surname>
                    <given-names>HC</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Chloride channel activity of bestrophin mutants associated with mild or late-onset macular degeneration.</article-title>
                <source>Invest Ophthalmol Vis Sci</source>
                <volume>48</volume>
                <fpage>4694</fpage>
                <lpage>705</lpage>
                <pub-id pub-id-type="pmid">17898294</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.yu.2008.5660">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiao</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cui</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartzell</surname>
                    <given-names>HC</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The Best disease-linked Cl- channel hBest1 regulates Ca V 1 (L-type) Ca2+ channels via src-homology-binding domains.</article-title>
                <source>J Neurosci</source>
                <volume>28</volume>
                <fpage>5660</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">18509027</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.zhao.2012.866">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grob</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corey</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krupa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Du</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quach</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>PX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kozak</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>A novel compound heterozygous mutation in the BEST1 gene causes autosomal recessive Best vitelliform macular dystrophy.</article-title>
                <source>Eye (Lond)</source>
                <year>2012</year>
                <volume>26</volume>
                <fpage>866</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">22422030</pub-id>
              </element-citation>
            </ref>
            <ref id="bvd.REF.zhuk.2006.811">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhuk</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>AO</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Peripherin/RDS and VMD2 mutations in macular dystrophies with adult-onset vitelliform lesion.</article-title>
                <source>Mol Vis</source>
                <volume>12</volume>
                <fpage>811</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16885924</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="bvd.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="bvd.Author_History">
          <title>Author History</title>
          <p>Thomas Lee, MD (2003-present)Ian M MacDonald, MD, CM (2003-present)Dean Y Mah, MSc, MD; University of Alberta (2003-2009)</p>
        </sec>
        <sec id="bvd.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>12 December 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>7 April 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>8 December 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>27 October 2003 (imd) Revision: sequence analysis clinically available</p>
            </list-item>
            <list-item>
              <p>30 September 2003 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>14 July 2003 (imd) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="bvd.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Vitelliform stage (Stage 2)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bvd-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="bvd.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Pseudohypopyon (Stage 3)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bvd-Image002" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="bvd.F3" orientation="portrait">
          <label>Figure 3. </label>
          <caption>
            <p>Central scarring (Stage 4b)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bvd-Image003" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
